Myocarditis Associated with mRNA COVID-19 Vaccination
Introduction
Mass immunization campaigns have been initiated to contain the ongoing COVID-19 pandemic. COVID-19 vaccines currently authorized for emergency use in the United States include BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and JNJ-78436735 (Johnson & Johnson). Recently the lay press has reported concerns for vaccine-associated myocarditis (1). In this work, we describe cardiac MRI findings in patients with myocarditis detected shortly after COVID-19 mRNA vaccination.
Materials and Methods
In this retrospective institutional review board–approved and Health Insurance Portability and Accountability Act–compliant study, cardiac MRI examinations performed at our institution between January 1 and May 25, 2021, were reviewed for MRI findings of myocarditis and pericarditis. Subsequently, electronic health records were reviewed, and all patients who received COVID-19 vaccine preceding cardiac MRI were included (consecutive sample). Informed consent was waived per institutional review board protocol. Patients with a history of prior COVID-19 were excluded.
Cardiac MRI was performed at 1.5 T or 3.0 T (GE Healthcare) and evaluated as recently described (2). Clinical radiology reports were reviewed by three cardiovascular radiologists (J.S., S.B.R., and D.A.B., with 7–27 years of experience) in consensus. Demographic and clinical data including COVID-19 vaccination, 12-lead electrocardiogram finding, and serum markers of cardiac injury were documented.
Results
Five patients (4:1 male:female; age range, 17–38 years) were identified who had abnormal MRI findings and were vaccinated against COVID-19 prior to MRI. Cardiac troponin levels and electrocardiogram findings were abnormal in all patients. All patients were hospitalized due to acute onset of chest pain with diagnosis of acute myocarditis.
Patients 1–3 received their second dose of BNT162b2 vaccine 2 days, 3 days, and 2 days, respectively, before onset of chest pain. Patients 4 and 5 both received their second dose of mRNA-1273 at 3 days before onset of chest pain. In all patients, MRI showed myocarditis-like findings including nonischemic pattern of late gadolinium enhancement, corresponding signal abnormalities on T2-weighted images, and pericardial enhancement (Table, Figure). Diagnostic considerations included pulmonary embolus or acute coronary event with additional imaging-based testing (Table). Ipsilateral axillary lymphadenopathy to the vaccination site was identified in four patients. COVID-19 testing at the time of diagnosis (and history of prior COVID-19) were negative. No respiratory symptoms, prodrome, or skin rash were present prior to vaccination. Furthermore, medical history did not reveal any preexisting cardiac disease in these patients.
|
Discussion
In this work, we report the MRI findings of myocarditis in five patients who recently received mRNA COVID-19 vaccination. The clinical presentation (acute chest pain, abnormal troponin level, and electrocardiogram finding), temporal relationship, lymphadenopathy, and negative COVID-19 history raises concern for vaccine-related myocarditis. Because vaccine-related myocarditis is expected to be rare compared with typical viral myocarditis, the associations we observed do not indicate causation. However, the cases shown illustrate potential cardiac MRI findings that may be encountered by the imaging physician. Awareness of a possible association of vaccine with the clinical presentation of myocarditis or pericarditis may also be beneficial to reduce other diagnostic testing (eg, CT or MR angiography, scintigraphy).
To date, 627 cases of myocarditis following COVID-19 vaccination have been reported in the Centers for Disease Control and Preventionʾs Vaccine Adverse Event Reporting System, or VAERS, database (3). Because VAERS requires active reporting, there is a risk of bias, and the confidence in prior reports is unclear. Recently, several cases of acute myocarditis have been reported after receiving one or two doses of BNT162b2 or mRNA-1273 vaccine in adults and adolescents (4–8). The myocarditis-like MRI findings in these studies are consistent with those observed in our patients (5–8). Furthermore, news headlines from Israel have emerged (1), reporting myocarditis in 275 patients, the majority after the second dose of mRNA COVID-19 vaccine.
In general, establishing a causal link between myocarditis and vaccination is difficult (9), especially when the prevalence is rare. However, based on emerging data, pharmacovigilance for myocardial injury related to mRNA-based vaccination should be encouraged during the ongoing vaccination program. Although rare, prior vaccines have also been linked to myocarditis (9).
Myocardial biopsy was not performed in our patients per local standard of care for mild uncomplicated myocarditis. Viral serologies were not performed, and are typically only recommended for fulminant myocarditis (10).
In conclusion, vaccine-related myocardial injury should be considered in the differential diagnosis in patients recently vaccinated against COVID-19 who present with acute chest pain.
Author Contributions
Author contributions: Guarantors of integrity of entire study, J.S., T.M.G., S.B.R.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; approval of final version of submitted manuscript, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, J.S., D.A.B., W.S.B., T.M.G., S.B.R.; clinical studies, all authors; and manuscript editing, all authors
References
- 1. . Israel sees probable link between Pfizer vaccine and myocarditis cases Pfizer vaccine and myocarditis cases. 2021; https://www.reuters.com/world/middle-east/israel-sees-probable-link-between-pfizer-vaccine-small-number-myocarditis-cases-2021-06-01/ Published 2021. Accessed June 2, 2021. Google Scholar
- 2. . Evaluation for Myocarditis in Competitive Student Athletes Recovering from Coronavirus Disease 2019 with Cardiac Magnetic Resonance Imaging. JAMA Cardiology. 2021;6(8): Google Scholar
- 3.
United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC)/Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 6/18/2021, CDC WONDER On-line Database http://wonder.cdc.gov/vaers.html. Accessed July 1, 2021. Google Scholar - 4. . Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int J Cardiol Heart Vasc. 2021;34:100774. Crossref, Medline, Google Scholar
- 5. . Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021; doi: https://doi.org/10.1001/jamacardio.2021.2833Published online June 29, 2021. Google Scholar
- 6. . Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: a report of two cases. Clin Imaging 2021;78:247–249. Crossref, Medline, Google Scholar
- 7. . Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J 2021. https://doi.org/10.1097/INF.0000000000003235Published online June 2, 2021. Google Scholar
- 8. . Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. 2021; doi: https://doi.org/10.1001/jamacardio.2021.2828 Published online June 29, 2021. Google Scholar
- 9. . Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. Int J Cardiol. 2018;273 :183–186. Crossref, Google Scholar
- 10. . Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement from the American Heart Association. Circulation. 2020;141(6 ): e69–e92. Google Scholar
Article History
Received: June 4 2021Revision requested: June 30 2021
Revision received: July 2 2021
Accepted: July 7 2021
Published online: July 20 2021
Published in print: Nov 2021